Fig. 1

Survival grouped by magnesium level. A Progression-free survival of patients with lymphoma in the ZUMA-1 cohort undergoing CAR-T by day -5 before the start of lymphodepleting chemotherapy serum magnesium level. p = 0.022. B Overall survival of patients with lymphoma in the ZUMA-1 cohort undergoing CAR-T by day -5 before the start of lymphodepleting chemotherapy serum magnesium level. p = 0.0013. (Low ≤ 1.7 mg/dL; Normal = 1.7 to < 2.0 mg/dL; High ≥2.0 mg/dL) C Progression-free survival of patients with lymphoma in the SOC cohort undergoing CAR-T by day -5 before the start of lymphodepleting chemotherapy serum magnesium level. p = 0.03. D Overall survival of patients with lymphoma in the SOC cohort undergoing CAR-T by day -5 before the start of lymphodepleting chemotherapy serum magnesium level. p = 0.13